Centrally Mediated Abdominal Pain Syndrome (CAPS)
- Home
- Solutions
- Other Gastrointestinal Disorders
- Centrally Mediated Abdominal Pain Syndrome (CAPS)
Centrally mediated abdominal pain syndrome (CAPS), classified under functional abdominal pain syndrome within the Rome III criteria, involves extensive abdominal aches. Protheragen is focused on progress in rare gastrointestinal diseases, particularly CAPS. As a leading research service provider, we provide comprehensive drug development solutions with a special focus on CAPS and its complexities.
Centrally mediated abdominal syndrome (CAPS) is one of the so-called disabilities of the gut-brain interaction (DGBI), also known as functional gastrointestinal disorders (FGID). It is characterized by persistent or almost persistent abdominal pain or repeated episodes of pain for more than six months. CAPS is less common than other functional gastrointestinal diseases such as irritable bowel syndrome (IBS) and functional dyspepsia.
Fig.1 Abdominal pain pathways. (Kim, H. J., and Kim, H. J., 2021)
The pathogenesis of CAPS might be linked to gut-brain axis abnormalities. Abdominal pain, dyspepsia, and constipation could be possible manifestations of the functional impairment of the gut-brain axis. CAPS is believed to result from central sensory processing control rather than peripheral stimulation. Once central sensitization has developed, abdominal pain can be present independent of peripheral stimulation. Some CAPS researchers reasoned that the overriding factor initiating CAPS was dysfunction in the descending pain control system, while the mental disorder appeared to be a predisposing factor.
Fig.2 Symptom-related behaviors are common in CAPS. (Keefer, L., et al., 2016)| Drug Names | Mechanism of Action | Targets | Research Phase |
| Duloxetine | Simultaneously inhibits the reuptake of both serotonin and norepinephrine. | NET | Approved |
| Pregabalin | Effective for CAPS abdominal pain and associated somatic or anxiety symptoms. | CACNA2D1 | Phase IV |
| Lidocaine | Reduces peak currents of Na+ channels and reduces neuronal excitability and, consequently, the sensation of pain. | VGSC | N/A |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Comprised of veteran researchers, scientists, and professionals, our team's passion lies in striving towards understanding and treating CAPS. We understand the nuances of each research project and create customized research plans that address the very specific therapeutic research requirements of this condition. From preclinical research to drug development, we offer a complete suite of services including diagnostic, therapeutic, and disease model development services to make the process effortless for our clients.
By replicating aspects of human biology, animal models assist in the testing of new hypotheses and the assessment of possible therapeutic strategies within a controlled and reproducible experimental setting. With the help of modern technologies and methods, our expert team provides services for creating, developing, and validating animal models for CAPS that provide support for the development of innovative therapies.
Colorectal Distention Models
Colonic distension can be used to simulate visceral pain and allows researchers to evaluate sensory processing and the role of the central nervous system in pain perception.
Leveraging cutting-edge technologies and methodologies, Protheragen guarantees that the highest standards of scientific research are integrated into our drug development services, which include pharmacokinetics and drug safety evaluation. We have demonstrated success with many clients and have built relationships as a dependable collaborator in the research of rare diseases of the gastrointestinal tract. Please reach out to discuss these diseases and our services in greater detail.
Reference
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.